Certara Launches its Phoenix QT+ Cardiac Safety Assessment Tool
Product helps to determine whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias
Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Phoenix QT+ cardiac safety assessment tool. This product provides data processing, statistical, and modeling capabilities to determine whether a drug candidate prolongs cardiac repolarization.
It is important to know whether a drug candidate causes disruption of the electrical potential in the left ventricular cardiac cells and QT prolongation because they are surrogates for potentially-fatal arrhythmias.
For that reason, systemic new drug candidates are required to undergo a Thorough QT (TQT) study under the ICH E14 Guidelines (ICH, 2005). The TQT study is a clinical pharmacology study designed to demonstrate that a drug does not prolong the QT/QTc interval in healthy volunteers.
Phoenix QT+ performs a quick but comprehensive analysis of electrocardiogram (ECG) interval data collected in TQT studies and sub-studies in other clinical trials to determine whether that is the case. It also supports concentration-QTc modeling of pooled data collected in early phase 1 studies. Results are displayed automatically in worksheets and graphics.
“Phoenix QT+ is an easy tool to use that empowers scientists to conduct the requisite data analysis themselves. This enables them to quickly determine a drug’s cardiac safety risk profile and make swifter decisions regarding the need for ECG monitoring in clinical studies,” said Certara Vice President and Lead Scientist Christine Garnett, Pharm.D. “They may decide to select a different dose that is less likely to prolong the QT interval, or identify sub-populations that are at lower risk of experiencing that response,” she added.
Phoenix QT+ is Certara’s second cardiac safety tool; it introduced the Cardiac Safety Simulator (CSS), an in-silico model of human ventricular heart cells, in mid-2013. When Certara’s CSS is integrated with its Simcyp Population-based Simulator, it permits the in-vitro to in-vivo extrapolation of pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
